ArticleGastroenterology2009
Saccharomyces boulardii inhibits EGF receptor signaling and intestinal tumor growth in Apc(min) mice.
Article in Gastroenterology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- Efficacy and safety of probiotics combined with bismuth-containing quadruple therapy forFrontiers in microbiology · 2025Pooled it
- Multi-omics analysis of saccharomyces boulardii supplementation reveals coordinated microbiome, metabolic, and immune signaling changes accompanying tumor suppression.Gut microbes · 2026Article
- The mycobiome, virome and archaeome in gastrointestinal cancers: molecular pathogenesis and therapeutic intervention.Molecular cancer · 2026Review
- The role of gut microbiota and its metabolites in preventing oncogenesis.Frontiers in cell and developmental biology · 2026Review
- Brewing a Cure: Engineering Yeast to Reduce Inflammation-Driven Tumors.Digestive diseases and sciences · 2025Article
- Fungal microbiota signatures anticipate neoadjuvant immunochemotherapy outcomes in esophageal cancer.Journal for immunotherapy of cancer · 2025Article
- Molecular Mechanisms of Probiotic Action Against Gastrointestinal Cancers.International journal of molecular sciences · 2025Review
- Engineered Probiotic Saccharomyces boulardii Reduces Colitis-Associated Colorectal Cancer Burden in Mice.Digestive diseases and sciences · 2025Article
- Mycobiome: an underexplored kingdom in cancer.Microbiology and molecular biology reviews : MMBR · 2025Review
- The Anti-Inflammatory, Immunomodulatory, and Pro-Autophagy Activities of Probiotics for Colorectal Cancer Prevention and Treatment: A Narrative Review.Biomedicines · 2025Review
- Gut Mycobiome: Latest Findings and Current Knowledge Regarding Its Significance in Human Health and Disease.Journal of fungi (Basel, Switzerland) · 2025Review
- A yeast-based oral therapeutic delivers immune checkpoint inhibitors to reduce intestinal tumor burden.Cell chemical biology · 2025Article
- The mycobiome in human cancer: analytical challenges, molecular mechanisms, and therapeutic implications.Molecular cancer · 2025Review
- Anticancer Properties of Probiotic Saccharomyces boulardii Supernatant on Human Breast Cancer Cells.Probiotics and antimicrobial proteins · 2022Article
- Probiotic as anti-colorectal cancer agents: Challenges and further perspective.Annals of medicine and surgery (2012) · 2022Article
- Review
- Probiotic YeastJournal of fungi (Basel, Switzerland) · 2022Review
- Effects of Probiotics at the Interface of Metabolism and Immunity to Prevent Colorectal Cancer-Associated Gut Inflammation: A Systematic Network and Meta-Analysis With Molecular Docking Studies.Frontiers in microbiology · 2022Article
- Diversity of the gut, vaginal and oral microbiome among pregnant women in South Africa with and without pre-eclampsia.Frontiers in global women's health · 2022Article
- ProbioticFood science & nutrition · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsSaccharomyces boulardii (Sb) is a probiotic yeast with anti-inflammatory and anti-microbial activities and has been used for decades in the prevention and treatment of a variety of human gastrointestinal disorders. We reported previously that Sb modulates host inflammatory responses through down-regulation of extracellular signal-regulated kinase (Erk)1/2 activities both in vitro and in vivo. The aim of this study was to identify upstream mediators responsible for extracellular signal-regulated kinase (Erk)1/2 inactivation and to examine the effects of Sb on tumor development in Apc(Min) mice.
methodsSignaling studies of colon cancer cells were done by western blot. Cell proliferation was measured by MTS and BrdU assay. Apoptosis was examined by flow cytometry, tunel assay and caspase assay. Apc(Min) mice were orally given Sb for 9 weeks before sacrifice for tumor analysis.
resultsWe found that the epidermal growth factor receptor (EGFR) was deactivated upon exposure to Sb, leading to inactivation of both the EGFR-Erk and EGFR-Akt pathways. In human colonic cancer cells, Sb prevented EGF-induced proliferation, reduced cell colony formation, and promoted apoptosis. HER-2, HER-3, and insulin-like growth factor-1 receptor were also found to be inactivated by Sb. Oral intake of Sb reduced intestinal tumor growth and dysplasia in C57BL/6J Min/+ (Apc(Min)) mice.
conclusionsThus, in addition to its anti-inflammatory effects, Sb inhibits EGFR and other receptor tyrosine kinase signaling and thereby may also serve a novel therapeutic or prophylactic role in intestinal neoplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.